Chronic Lymphocytic Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Current treatment options for relapsed CLL
The management of relapsed chronic lymphocytic leukemia (CLL) is a complex and difficult issue. We interviewed William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, on the subject at... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Genetic screening to inform CLL treatment
Biomarker screening has become an essential component of constructing treatment plans in chronic lymphocytic leukemia (CLL). In this video, recorded at the 23rd Congress of the European Hematology Ass... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel agent combinations: the future of CLL
There has been an influx of novel agents in the field of chronic lymphocytic leukemia (CLL) in recent years. These include venetoclax, ibrutinib and obinutuzumab. In this video, recorded at the 23rd C... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

BCL-2 inhibitors: the current landscape
BCL-2 inhibitors like ibrutinib and venetoclax have been used in the treatment of lymphoproliferative disorders like chronic lymphocytic leukemia (CLL) for long enough that mid-term effects of the age... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel agents in CLL: the current landscape
The development of novel agents for treating chronic lymphocytic leukemia (CLL) has transformed the field in recent years. In this video, recorded at the 23rd Congress of the European Hematology Assoc... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

TKIs in CLL: an overview
The use of tyrosine kinase inhibitors (TKIs) in chronic lymphocytic leukemia (CLL) is expanding. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Obinutuzumab increases survival in CLL patients with comorbidities
The CLL11 trial (NCT01998880) compared chlorambucil monotherapy with combination therapies of chlorambucil and anti-CD20 antibodies rituximab or obinutuzumab for chronic lymphocytic leukemia (CLL) in ... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

CAPTIVATE and beyond: combination therapies for CLL
Novel agent combination therapies are coming to the forefront of chronic lymphocytic leukemia (CLL) research. Here, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses a ... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Pulmonary infiltration of CLL: implications for treatment
In chronic lymphocytic leukemia (CLL), treatment is often delayed because patients develop infections. Florence Cymbalista, PhD, from the Hpital Avicenne, Bobigny, France, presented results at the 23... Author: VJHemOnc Added: 07/18/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 18, 2018 Category: Cancer & Oncology Source Type: podcasts

Outstanding results from CLARITY: a new CLL combination therapy
The CLARITY study (ISCRTN13751862) is the first clinical trial looking at the combination of venetoclax and ibrutinib for treating relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Peter H... Author: VJHemOnc Added: 07/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Key MRD monitoring techniques in CLL
It is important that current techniques for the monitoring of minimal residual disease (MRD) in chronic lymphocytic leukemia (CLL) are validated to ensure sensitivity and accuracy. Here, Peter Hillmen... Author: VJHemOnc Added: 07/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - July 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel agent combinations for CLL: ibrutinib, venetoclax, obinutuzumab and zanubrutinib
There are a growing number of investigations of novel combination therapies for chronic lymphocytic leukemia (CLL). These are discussed in this interview with Peter Hillman, MD, ChB, from Leeds Teachi... Author: VJHemOnc Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts

MURANO update: MRD negativity in CLL
The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL), for which further results were presented at the ... Author: VJHemOnc Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel CLL therapies: the future
The multitude of novel therapies in the field of chronic lymphocytic leukemia (CLL) paves the way for exciting future possibilities. In this interview, Jennifer Woyach, MD, of the Ohio State Universit... Author: VJHemOnc Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts

Promises and challenges in up-and-coming CLL therapies
Promising novel therapies are on the horizon within the field of chronic lymphocytic leukemia (CLL). Here, Jennifer Woyach, MD, of the Ohio State University Comprehensive Cancer Center, Columbus, OH, ... Author: VJHemOnc Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts